ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Cytek Biosciences (CTKB)
Cytek Biosciences stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
$5.98▲ +1.53%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Cytek Biosciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Cytek Biosciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Cytek Biosciences a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $5.41 and $6.53; in 9 out of 10, between $4.58 and $7.71. Estimated annual volatility is 53%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $763M
- 52-week high
- $6.21
- 52-week low
- $3.31
- Revenue (12 months)
- $207M
- Revenue growth (YoY)
- +0.5%
- Gross margin
- 51.8%
- Operating margin
- -20.0%
- Net margin
- -33.0%
- Return on equity
- -23.0%
- Free cash flow (12 months)
- $9.3M
- Beta
- 1.19
What this means
ATLAS does not publish a fair value for CTKB right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CTKB has traded between $3.31 and $6.21. Today it is 3.7% below that high and 81% above its low.
On the business: revenue grew 0.5% year over year; net margin is 33.0%.
Its beta is 1.19: it tends to move more than the market, both up and down.
About the company
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications.
Want to see everything about Cytek Biosciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Cytek Biosciences do?
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications.
What is the chance CTKB goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, CTKB ends the month between $5.41 and $6.53.
How big is Cytek Biosciences and what is its P/E ratio?
Cytek Biosciences's market capitalization is $763M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is CTKB?
ATLAS estimates annual volatility at 53%. In a typical month, half of the outcomes end between $5.41 and $6.53.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer